Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Rhea-AI Summary
Axogen (Nasdaq: AXGN) announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. Phone access is via (877) 407-0993 or (201) 689-8795, with webcast and replay on the Axogen Investors webpage.
Positive
- None.
Negative
- None.
News Market Reaction – AXGN
In the Jul 15 session, AXGN declined 0.13%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Earnings date notice | Positive | +3.0% | Scheduled Q1 2026 results date and investor call details. |
| Feb 10 | Earnings date notice | Positive | +1.7% | Announced Q4 and full-year 2025 results release timing and call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-date announcements have historically coincided with modestly positive next-day moves for Axogen.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com